Imagining perfect molecules using AI - a benchmarking system for generative chemistry

November 30, 2020

November 30, 2020 - Insilico Medicine, a leading company in AI-powered drug discovery, today announced that the paper titled "Molecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Models" was published in Frontiers in Pharmacology. In addition to the authors from Insilico Medicine and Neuromation, the author list includes Simon Johansson and Hongming Chen from AstraZeneca, Benjamin Sanchez Lengeling from Harvard University, and Alan Aspuru-Guzik from Vector Institute, Department of Computer Science, University of Toronto, and Canadian Institute for Advanced Research (CIFAR).

In 2018, Insilico Medicine presented Molecular Sets (MOSES) benchmarking platform that was employed by multiple research groups since then. MOSES contains a carefully curated dataset, a set of metrics, and a wide variety of baselines for comparing generative models for chemistry. Over the last two years, we extended the repository with new baselines, enhanced evaluation protocols, and implemented simple routines for using MOSES out of the box. Today, Insilico Medicine announces that the manuscript describing the platform has been accepted for publication in Frontiers in Pharmacology, "Artificial intelligence for Drug Discovery and Development" special issue. The paper will soon be available here: https://www.frontiersin.org/articles/10.3389/fphar.2020.565644. For more information on MOSES, please visit the GitHub repository https://github.com/molecularsets/moses.

"With the rapid development of new generative chemistry, it is crucial to compare machine learning models in a unified way; with MOSES, we can easily compare new models with existing approaches without reimplementing all the baselines. MOSES is a result of tight collaboration between multiple generative chemistry labs; together we polished the platform over the last two years and made it as simple and intuitive as possible. We are glad to help researchers obtain interpretable, reproducible results with our platform.", said Daniil Polikovskiy, senior author of the paper.

To cite the paper: https://www.frontiersin.org/articles/10.3389/fphar.2020.565644
-end-
Media Contact

For further information, images, or interviews, please contact: ai@insilico.com

About Insilico Medicine

Insilico Medicine develops software that leverages generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with specific properties. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trials outcomes. The company integrates two business models; providing AI-powered drug discovery services and software through its Pharma.AI platform (http://www.insilico.com/platform/) and developing its own pipeline of preclinical programs. The preclinical program is the result of pursuing novel drug targets and novel molecules discovered through its platforms. Since its inception in 2014, Insilico Medicine has raised over $52 million and received multiple industry awards. Insilico Medicine has also published over 100 peer-reviewed papers and has applied for over 25 patents. Website insilico.com

InSilico Medicine

Related Artificial Intelligence Articles from Brightsurf:

Physics can assist with key challenges in artificial intelligence
Two challenges in the field of artificial intelligence have been solved by adopting a physical concept introduced a century ago to describe the formation of a magnet during a process of iron bulk cooling.

A survey on artificial intelligence in chest imaging of COVID-19
Announcing a new article publication for BIO Integration journal. In this review article the authors consider the application of artificial intelligence imaging analysis methods for COVID-19 clinical diagnosis.

Using artificial intelligence can improve pregnant women's health
Disorders such as congenital heart birth defects or macrosomia, gestational diabetes and preterm birth can be detected earlier when artificial intelligence is used.

Artificial intelligence (AI)-aided disease prediction
Artificial Intelligence (AI)-aided Disease Prediction https://doi.org/10.15212/bioi-2020-0017 Announcing a new article publication for BIO Integration journal.

Artificial intelligence dives into thousands of WW2 photographs
In a new international cross disciplinary study, researchers from Aarhus University, Denmark and Tampere University, Finland have used artificial intelligence to analyse large amounts of historical photos from WW2.

Applying artificial intelligence to science education
A new review published in the Journal of Research in Science Teaching highlights the potential of machine learning--a subset of artificial intelligence--in science education.

New roles for clinicians in the age of artificial intelligence
New Roles for Clinicians in the Age of Artificial Intelligence https://doi.org/10.15212/bioi-2020-0014 Announcing a new article publication for BIO Integration journal.

Artificial intelligence aids gene activation discovery
Scientists have long known that human genes are activated through instructions delivered by the precise order of our DNA.

Artificial intelligence recognizes deteriorating photoreceptors
A software based on artificial intelligence (AI), which was developed by researchers at the Eye Clinic of the University Hospital Bonn, Stanford University and University of Utah, enables the precise assessment of the progression of geographic atrophy (GA), a disease of the light sensitive retina caused by age-related macular degeneration (AMD).

Classifying galaxies with artificial intelligence
Astronomers have applied artificial intelligence (AI) to ultra-wide field-of-view images of the distant Universe captured by the Subaru Telescope, and have achieved a very high accuracy for finding and classifying spiral galaxies in those images.

Read More: Artificial Intelligence News and Artificial Intelligence Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.